Navigation Links
NewLink Genetics Corporation Closes $7.5 Million Financing
Date:7/20/2009

AMES, Iowa, July 20 /PRNewswire/ -- NewLink Genetics Corporation announced today that it has secured $7.5 million in a Series D financing to accelerate the clinical development of its therapeutic cancer products. This financing involved additional funding from prior investors.

"NewLink has worked hard to become one of the leaders in the expanding field of cancer immunotherapy," said Dr. Charles Link, Chairman and Chief Executive Officer of NewLink Genetics Corporation. "The proceeds of this financing will allow us to both rapidly move our lead immunotherapy product for pancreatic cancer into pivotal clinical studies and to advance our IDO inhibitor, D-1MT, into multiple Phase 2 studies."

About NewLink Genetics Corporation

NewLink Genetics Corporation is a biopharmaceutical company applying innovative approaches to create new therapeutic agents for patients with cancer and infectious diseases. Its technologies are designed to enhance the patient's immune system, enabling the body's immune cells to attack their intended target.

    Contact

    NewLink Genetics Corporation
    Gordon Link, CFO, 515-296-4351


'/>"/>
SOURCE NewLink Genetics Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Viral Genetics Retires Nearly $3.5 Million Convertible Debt and Provides Updates on Capital Structure and Stock Issuances
2. Viral Genetics Information Now Available Through OTCIQ.com and Pink Sheets Website
3. Genomas and Institute of Living Among Organizers of Pharmacogenetics Symposium at 2009 Annual Meeting of the American Psychiatric Association
4. Interleukin Genetics to Present at the 2009 BIO Business Forum
5. deCODE genetics Announces First Quarter 2009 Financial Results
6. deCODE genetics Announces Webcast of Conference Call to Discuss First Quarter 2009 Financial Results
7. Ambry Genetics Announces the Addition of Array CGH Services Through Partnership With Baylor College of Medicine
8. SemBioSys Genetics Inc. obtains up to $1.5 million in funding from AVAC
9. AgFeed Industries Enters Into Hog Genetic Program Arrangement with Hypor, the Pig Breeding Division of Hendrix Genetics B.V.
10. deCODE genetics Announces Webcast of Conference Call to Discuss Full-year 2008 Financial Results
11. SemBioSys Genetics Inc. Announces Clinical Results with Plant-Produced Insulin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... Fla. , Feb. 16, 2017  MDNA ... revolutionizing the development of liquid biopsy tests based ... entered into an exclusive license agreement with its ... MDNA,s proprietary liquid biopsy test for prostate cancer, ... South Korea . This is the first ...
(Date:2/16/2017)... Mass. , Feb. 16, 2017   Biostage, ... the "Company"), a biotechnology company developing bioengineered organ implants ... esophagus, bronchus and trachea, announced today the closing on ... of 20,000,000 shares of common stock and warrants to ... proceeds of $8.0 million. The offering was priced at ...
(Date:2/16/2017)... Feb. 16, 2017  Champions Oncology, Inc. (NASDAQ: ... and sale of advanced technology solutions and products to ... announced the addition of new cohorts of PDX models ... models will expand Champions, product line in hepatocellular cancer, ... cancer, AML, and non-small cell lung cancer (including EGFR ...
(Date:2/16/2017)... and NEW YORK , Feb. ... near completion of their $7M Series B financing, adding ... of the $3.5M led by Mesa Verde Venture Partners ... These resources will be directed towards further accelerating commercial ... a comprehensive genomic profiling test and expanding the Paradigm ...
Breaking Biology Technology:
(Date:2/13/2017)...  RSA Conference -- RSA, a Dell Technologies business, ... enhance fraud detection and investigation across digital environments ... & Risk Intelligence Suite. The new platform is ... from internal and external sources as well as ... from targeted cybercrime attacks. "Fraudsters are ...
(Date:2/10/2017)... -- Research and Markets has announced the ... Scientific and Commercial Aspects" to their offering. ... Biomarkers play ... therapy for selection of treatment as well for monitoring the ... disease in modern medicine. Biochip/microarray technologies and next generation sequencing ...
(Date:2/8/2017)... NEW YORK , Feb. 8, 2017 /PRNewswire/ ... an individual,s voice to match it against a ... voice such as pitch, cadence, and tone are ... systems require minimal hardware installation, as most PCs ... remotely for different transactions. Voice recognition biometrics are ...
Breaking Biology News(10 mins):